Use of D-chiro-inositol in the treatment of conditions associated with hypothalamic gene expression

• US 20020032177A1
• Filed: 04/30/2001
• Published: 03/14/2002
• Est. Priority Date: 04/28/2000
• Status: Abandoned Application

• Current Assignee: Insmed Incorporated
• Original Assignee: INSMED Pharmaceuticals, Inc. (Insmed Incorporated)
• Inventors: Mobbs, Charles V., Allan, Geoffrey
• Application Number:
  US09/844,292
• Publication Number:
  US 20020032177A1
• Time in Patent Office: Days
• US Class Current: 514/129
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/047 having two or more hydroxy groups, e.g. sorbitol
• CPC Class Codes: A61K 31/075 Ethers or acetals
• CPC Class Codes: A61K 31/215 of carboxylic acids
• CPC Class Codes: A61K 31/28 Compounds containing heavy metals
• CPC Class Codes: A61K 31/357 having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
• CPC Class Codes: A61K 31/66 Phosphorus compounds
• CPC Class Codes: A61K 31/715 Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents

Abstract

The present invention relates to the use of D-chiro-inositol (DCI) as a regulator of hypothalamic gene expression and, more particularly, to the use of DCI and derivatives and metabolites thereof to treat neuroendocrine impairments such as obesity, polycystic ovarian syndrome (PCOS), impaired regulation of hormones during aging and to correct such neuroendocrine impairments and associated functions.

Claims

1. A method of improving hypothalamic gene expression in a mammal comprising the step of administering to said mammal an effective amount of D-chiro-inositol (DCI), or a derivative or metabolite thereof.

2. A method according to claim 1, wherein said mammal is a human.

3. A method according to claim 1, wherein said derivative or metabolite is selected from the group consisting of D-chiro-inositol phosphates, D-chiro-inositol esters, D-chiro-inositol ethers, D-chiro-inositol acetals, D-chiro-inositol ketals, D-chiro-inositol polysaccharide, D-chiro-inositol phospholipids and metal complexes of D-chiro-inositol.

4. A method according to claim 1, wherein said D-chiro-inositol is administered in combination with an insulin sensitizer.

5. A method according to claim 2, wherein said effective amount is a daily dosage between about 0.07 milligrams and about 3500 milligrams.

6. A method according to claim 5, wherein said D-chiro-inositol is administered orally.

7. A method of controlling the weight of a mammal comprising the step of administering to a mammal in need thereof an effective amount of D-chiro-inositol (DCI), or a derivative or metabolite thereof.

8. A method according to claim 7, wherein said mammal is a human.

9. A method according to claim 7, wherein said derivative or metabolite is selected from the group consisting of D-chiro-inositol phosphates, D-chiro-inositol esters, D-chiro-inositol ethers, D-chiro-inositol acetals, D-chiro-inositol ketals, D-chiro-inositol polysaccharide, D-chiro-inositol phospholipids and metal complexes of D-chiro-inositol.

10. A method according to claim 7, wherein said D-chiro-inositol is administered in combination with an insulin sensitizer.

11. A method according to claim 8, wherein said effective amount is a daily dosage between about 0.07 milligrams and about 3500 milligrams.

12. A method according to claim 11, wherein said D-chiro-inositol is administered orally.

14. A method according to claim 13, wherein said mammal is a human.

15. A method according to claim 13, wherein said derivative or metabolite is selected from the group consisting of D-chiro-inositol phosphates, D-chiro-inositol esters, D-chiro-inositol ethers, D-chiro-inositol acetals, D-chiro-inositol ketals, D-chiro-inositol polysaccharide, D-chiro-inositol phospholipids and metal complexes of D-chiro-inositol.

16. A method according to claim 13, wherein said D-chiro-inositol is administered in combination with an insulin sensitizer.

17. A method according to claim 14, wherein said effective amount is a daily dosage between about 0.07 milligrams and about 3500 milligrams.

18. A method according to claim 17, wherein said D-chiro-inositol is administered orally.

20. A method according to claim 19, wherein said mammal is a human.

21. A method according to claim 19, wherein said derivative or metabolite is selected from the group consisting of D-chiro-inositol phosphates, D-chiro-inositol esters, D-chiro-inositol ethers, D-chiro-inositol acetals, D-chiro-inositol ketals, D-chiro-inositol polysaccharide, D-chiro-inositol phospholipids and metal complexes of D-chiro-inositol.

22. A method according to claim 19, wherein said D-chiro-inositol is administered in combination with an insulin sensitizer.

23. A method according to claim 20, wherein said effective amount is a daily dosage between about 0.07 milligrams and about 3500 milligrams.

24. A method according to claim 23, wherein said D-chiro-inositol is administered orally.

13. A method of increasing serum leptin in a mammal comprising the step of administering to a mammal an effective amount of D-chiro-inositol (DCI), or a derivative or metabolite thereof.

19. A method for the prophylaxis or treatment of diseases or disorders associated with abnormal hypothalamic gene expression comprising the step of administering to a mammal in need thereof an effective amount of D-chiro-inositol (DCI), or a derivative or metabolite thereof.